Chasing Dreams After Disability – Meet The Stubborn Baker
By Codi Darnell August 31, 2021 How many people can look at their chosen career and say “I chased my dream”? For someone with a disability, breaking into the working world can be a challenge at the best of times, but chasing a dream that’s been labelled “not for you” has the potential to truly […]
NervGen Pharma Provides an Operational Update on its Ongoing Phase 1 Clinical Trial and Reports Second Quarter 2021 Results
Vancouver, Canada. August 19, 2021 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today is providing an update on its Phase I clinical trial and is reporting its financial results for the second quarter […]
Peer Support and Spinal Cord Injury: A Look at the Documentary “Re-Inventing the Wheel”
By Codi Darnell August 17, 2021 People come into our lives at different times for different reasons. We connect with them based on mutual interests or shared experiences, forming relationships that help us to feel less alone in the world. Mothers need other mothers, fathers need other fathers, and people with spinal cord injuries (“SCI”) […]
NervGen Pharma and Massachusetts General Hospital Collaborate on Preclinical Studies in Alzheimer’s Disease / Dr. Ksenia Kastanenka to Study NVG-291’s Potential to Promote Repair in Alzheimer’s Disease Models
Vancouver, Canada. August 9, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, announced today it has entered into a research collaboration with Dr. Ksenia Kastanenka of Massachusetts General Hospital (MGH) to study the […]
NervGen Pharma Corp. Closes Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, Canada. August 5, 2021— NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” the “Company”), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, is pleased to announce that it has closed a […]
Train Airline Staff to Understand the Value of a Mobility Device and Maybe Then They’ll Stop Damaging Our Wheelchairs
By Codi Darnell August 3, 2021 Like so many people, I haven’t seen the inside of an airplane since before COVID became a household name. Even those who were ready and willing to jet off during the pandemic were met with the unwelcome reality that air travel was not accessible to them, that it was […]
NervGen Pharma Grants Stock Options
Vancouver, Canada. July 16, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced that the Company has granted 125,000 incentive stock options to existing consultants providing investor relations services, 25,000 of which […]
NervGen Pharma Establishes Multiple Sclerosis Clinical Advisory Board / NervGen Supports World Brain Day on July 22 to “Stop Multiple Sclerosis”
Vancouver, Canada. July 15, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced the formation of its Multiple Sclerosis (MS) Clinical Advisory Board comprised of six world-class scientific and clinical researchers in […]
The Outdoor Diaries: Andy McKenna, Multiple Sclerosis and Mountain Biking
By Codi Darnell July 20, 2021 Welcome to our blog series: The Outdoor Diaries. This series is about exploring the natural world from the perspective of people with chronic conditions and/or mobility issues. While the benefits of nature are for everybody, access to it isn’t always quite as simple. There is nothing like a diagnosis […]
NervGen Pharma Expands Alzheimer’s Disease Scientific Advisory Board
Vancouver, Canada. July 12, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced the addition of three world-class scientists and clinical researchers to its Alzheimer’s Disease Scientific Advisory Board. Drs. Martin Farlow, […]
